Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project

Bie Verbist, Günter Klambauer, Liesbet Vervoort, Willem Talloen, Ziv Shkedy, Olivier Thas, Andreas Bender, Hinrich W. H. Göhlmann, Sepp HochreiterDrug 2015 · DOI

Abstract

The pharmaceutical industry is faced with steadily declining R&D efficiency which results in fewer drugs reaching the market despite increased investment. A major cause for this low efficiency is the failure of drug candidates in late-stage development owing to safety issues or previously undiscovered side-effects. We analyzed to what extent gene expression data can help to de-risk drug development in early phases by detecting the biological effects of compounds across disease areas, targets and scaffolds. For eight drug discovery projects within a global pharmaceutical company, gene expression data were informative and able to support go/no-go decisions. Our studies show that gene expression profiling can detect adverse effects of compounds, and is a valuable tool in early-stage drug discovery decision making.
BibTeX
@inproceedings{verbist2015using,
  author = {Bie Verbist and Günter Klambauer and Liesbet Vervoort and Willem Talloen and Ziv Shkedy and Olivier Thas and Andreas Bender and Hinrich W. H. Göhlmann and Sepp Hochreiter},
  title = {{Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project}},
  booktitle = {Drug},
  year = {2015},
  doi = {10.1016/j.drudis.2014.12.014},
}

Loading related content...

Figure